MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 15, 2006; DOI: 10.1124/mol.106.024042


0026-895X/06/7003-1022-1032$20.00
Mol Pharmacol 70:1022-1032, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.106.024042v1
70/3/1022    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frizelle, P. A.
Right arrow Articles by Wyllie, D. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frizelle, P. A.
Right arrow Articles by Wyllie, D. J. A.

Equilibrium Constants for (R)-[(S)-1-(4-Bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic Acid (NVP-AAM077) Acting at Recombinant NR1/NR2A and NR1/NR2B N-Methyl-D-aspartate Receptors: Implications for Studies of Synaptic TransmissionFormula

Pamela A. Frizelle, Philip E. Chen, and David J. A. Wyllie

Centre for Neuroscience Research, University of Edinburgh, Edinburgh, United Kingdom

We have quantified the effects of the N-methyl-D-aspartate (NMDA) receptor antagonist (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) at rat recombinant N-methyl-D-aspartate receptor (NR)1/NR2A and NR1/NR2B NMDA receptors expressed in Xenopus laevis oocytes. We observed no difference in the steady-state levels of inhibition produced by NVP-AAM077 when it was either preapplied or coapplied with glutamate. The IC50 values for NVP-AAM077 acting at NR1/NR2A NMDA receptors were, as expected, dependent on the glutamate concentration used to evoke responses, being 31 ± 2 nM (with glutamate at its EC50 concentration) and 214 ± 10 nM (at 10 times the EC50 concentration). Schild analysis confirmed that the antagonism produced by NVP-AAM077 at NR1/NR2A NMDA receptors was competitive and gave an estimate of its equilibrium constant (KB) of 15 ± 2 nM. Furthermore, Schild analysis of an NMDA receptor carrying a threonine-to-alanine point mutation in the NR2A ligand binding site indicated that NVP-AAM077 still acted in a competitive manner but with its KB increased by around 15-fold. At NR1/NR2B NMDA receptors, NVP-AAM077 displayed reduced potency. An IC50 value of 215 ± 13 nM was obtained in the presence of the EC50 concentration of glutamate (1.5 µM), whereas a value of 2.2 ± 0.14 µM was obtained with higher (15 µM) glutamate concentrations. Schild analysis gave a KB for NVP-AAM077 at NR2B-containing receptors of 78 ± 3 nM. Finally, using a kinetic scheme to model "synaptic-like" activation of NMDA receptors, we show that the difference in the equilibrium constants for NVP-AAM077 is not sufficient to discriminate between NR2A-containing or NR2B-containing NMDA receptors.


Received March 30, 2006; accepted June 15, 2006

Address correspondence to: Dr. David J. A. Wyllie, Centre for Neuroscience Research, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK. E-mail: dwyllie1{at}staffmail.ed.ac.uk




This article has been cited by other articles:


Home page
J. Physiol.Home page
S. L. C. Brothwell, J. L. Barber, D. T. Monaghan, D. E. Jane, A. J. Gibb, and S. Jones
NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones
J. Physiol., February 1, 2008; 586(3): 739 - 750.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
D. C. Wrighton, E. J. Baker, P. E. Chen, and D. J. A. Wyllie
Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes
J. Physiol., January 1, 2008; 586(1): 211 - 225.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
P. E. Chen, M. T. Geballe, E. Katz, K. Erreger, M. R. Livesey, K. K. O'Toole, P. Le, C. J. Lee, J. P. Snyder, S. F. Traynelis, et al.
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes
J. Physiol., January 1, 2008; 586(1): 227 - 245.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
S. Papadia and G. E. Hardingham
The Dichotomy of NMDA Receptor Signaling
Neuroscientist, December 1, 2007; 13(6): 572 - 579.
[Abstract] [PDF]


Home page
J. Physiol.Home page
F. X. Soriano and G. E. Hardingham
Compartmentalized NMDA receptor signalling to survival and death
J. Physiol., October 15, 2007; 584(2): 381 - 387.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Q. Chen, S. He, X.-L. Hu, J. Yu, Y. Zhou, J. Zheng, S. Zhang, C. Zhang, W.-H. Duan, and Z.-Q. Xiong
Differential Roles of NR2A- and NR2B-Containing NMDA Receptors in Activity-Dependent Brain-Derived Neurotrophic Factor Gene Regulation and Limbic Epileptogenesis
J. Neurosci., January 17, 2007; 27(3): 542 - 552.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics